| ||||||||
|
| Men's Health Forum: This is a discussion on Transdermal versus oral DHEA within the Anabolic Steroids forums, part of the extensive steroid information at MESO-Rx; Originally Posted by SPE Here is an interesting study on transdermal DHEA. From what I can tell, the dose used ... |
| |||||||
![]() |
| | LinkBack | Thread Tools | Display Modes |
| |||
| Quote:
Quote:
J Clin Endocrinol Metab. 1999 Jun;84(6):2170-6. [PMID: 10372727] Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. Arlt W, Haas J, Callies F, Reincke M, Hubler D, Oettel M, Ernst M, Schulte HM, Allolio B. The author makes a series of statements in which he cites the 1997 Labrie study (above), saying: "Labrie et al. (19) administered a 20% DHEA cream in a daily dose of 10 mL for 14 days to a total of eight elderly men and women and found no significant increase in serum estrogen levels in either gender. These results differ from the findings of our study and those of Young et al. (18), but may be explained by the route of DHEA administration. As previously reported for transvaginal (20) and sublingual (13) administration of DHEA, Labrie et al. (18) also described an increased DHEA/DHEAS ratio after percutaneous DHEA administration compared to oral ingestion. Although many tissues contain sulfotransferases (21, 22) and may contribute to the peripheral conversion of DHEA to DHEAS, the hepatic sulfotransferase activity seems to be of predominant importance and is bypassed by nonoral DHEA administration due to avoidance of the hepatic first pass effect. An increased DHEA/DHEAS ratio may lead to a reduced conversion of DHEA to androgens and/or estrogens inside peripheral target cells, as DHEAS has a much longer half-life than DHEA, and it can be continuously converted back to DHEA by widespread tissue sulfatase activity (23, 24, 25, 26) followed by further bioconversion. Furthermore, avoidance of the first pass effect by nonoral administration of DHEA also leads to avoidance of hepatic aromatase and 5-reductase activities. This may explain a lack of conversion to estrogens in men as well as the reduced conversion to androgens in women after percutaneous DHEA administration (19). This view is supported by the data of Casson et al. (20), who found an increase in DHEA, but not in DHEAS and T, after transvaginal DHEA administration. Serum estrogen levels were not reported in this study (20). In agreement with our results, Labrie et al. (19) and Morales et al. (12) found no significant changes in serum T and DHT in their elderly male volunteers, whereas Young et al. (18) in their patients with hypopituitarism (including six men with unreplaced secondary hypogonadism) reported a slight, but significant, increase in serum androgens still below the normal range for men even after the administration of 200 mg DHEA. However, although total T and DHT remained unaffected in our male volunteers, a small, but significant, increase in serum free T was observed. This may be explained by transient interference of DHEA and DHEAS with binding proteins (e.g. competitive binding of DHEA and free T to SHBG or albumin) rather than by changes in binding protein concentrations. Both DHEA and T bind to SHBG and albumin (27, 28), and the rapid increase in DHEA as well as in DHEAS after oral ingestion of DHEA may be sufficient to displace a significant percentage of the protein-bound fraction of T. However, the increase in free T was short-lived and is most likely of minor importance. Additionally, in our male volunteers a significant increase in serum ADG, a major metabolite of DHT and also of androstenedione, was observed. This may indicate an enhanced conversion of DHEA to androgens inside peripheral target cells that is not reflected by circulating androgen concentrations. A DHEA-induced increase in androgenic capacity in men may be supported by the findings of Yen et al. (13), who described increased muscular strength and decreased body fat mass in men after 6 months of treatment with a daily dose of 100 mg DHEA, but this may also be a consequence of the reported increase in insulin-like growth factor I (13). In accordance with previous results both in men (12, 19) and women (12, 13, 17, 19, 29), DHEA administration to our male volunteers also led to a significant increase in serum androstenedione. Thus, DHEA induces a significant increase in serum androstenedione in both sexes, but the direction of further bioconversion may differ depending on the surrounding hormonal background, which may affect peripheral 17ß-hydroxysteroid dehydrogenase, 5-reductase, and aromatase activities." Full text is available here: http://jcem.endojournals.org/cgi/content/full/84/6/2170 Frank |
| Sponsored Links |
| |||
|
Hi rgkstl, That's what I'm worried about alright (potential prostate problems), and my experience with saw palmetto hasn't been good so far because of the side effects (headache, congestion, fatigue). The article/study below initially raised the potential ADG concern. (I haven't been able to get a hold of the fulltext.) Frank [Abstract:] Fertil Steril. 2004 Mar;81(3):595-604. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Acacio BD, Stanczyk FZ, Mullin P, Saadat P, Jafarian N, Sokol RZ. Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. OBJECTIVE: To determine the effects of dehydroepiandrosterone (DHEA) supplementation on the pharmacokinetics of DHEA and its metabolites and the reproductive axis of healthy young men. DESIGN: A prospective, randomized, double-blind, placebo-controlled pharmacokinetic study. SETTING: General Clinical Research Center and laboratories at the Keck School of Medicine of the University of Southern California, Los Angeles, California. PATIENT(S): Fourteen healthy men, ages 18-42 years. INTERVENTION(S): Daily oral administration of placebo (n = 5), 50 mg DHEA (n = 4), or 200 mg DHEA (n = 5) for 6 months. Blood samples were collected at frequent intervals on day 1 and at months 3 and 6 of treatment. MAIN OUTCOME MEASURE(S): Quantification of DHEA, DHEA sulfate (DHEAS), androstenedione, T, E(2), dihydrotestosterone (DHT), and 5alpha-androstane-3alpha-17beta-diol glucuronide (ADG). Physical examination, semen analysis, serum LH, FSH, prostate-specific antigen, and general chemistries were carried out. RESULT(S): Baseline DHEA, DHEAS, and ADG levels increased significantly from day 1 to months 3 and 6 in the DHEA treatment groups but not in the placebo group. No significant changes were observed in pharmacokinetic values. Clinical parameters were not affected. CONCLUSION(S): DHEA, DHEAS, and ADG increased significantly during 6 months of daily DHEA supplementation. Although the pharmacokinetics of DHEA and its metabolites are not altered, sustained baseline elevation of ADG, a distal DHT metabolite, raises concerns about the potential negative impact of DHEA supplementation on the prostate gland. |
| |||
|
Zinc, Vit. E, Selenium, Lycopene and Stinging Nettle are ideal. Briefly here... Later in life, testosterone can undergo unhealthy changes that can harm your prostate. Zinc may be able to decrease the amount of this 'bad' testosterone your prostate absorbs. All natural vitamin E is a powerful ally for complete prostate health. And selenium works with vitamin E to protect your cells. Together, they're a powerful defense against cell damage. Stinging Nettle can reduce the amount of free (active) testosterone circulating in the blood and help to inhibit aromatase, one of the enzymes responsible for testosterone synthesis. In my opinion, vit. E, Selenium and Lycopene not withstanding(as they should always be part of your regimine), Saw and Stinging Nettle are tops. Most good prostate formulas you find on the market will contain these. You can for sure do them as a stand alone though. |
| |||
| Quote:
__________________ Don't believe anything you hear and only half of what you see. Phil |
| |||
|
Two points from my studies: Oral DHEA is poorly bio available, like 3% so to get much you need major doses. Most studies report little increased levels of any androgen from oral while transdermal may be as high as 30%. While you are doing the Pub Meds look at a recent study on the increase in HGH from Transdermal DHEA. Very interesting. I do both a morning and an evening trans DHEA one in conjunction with my trans T. As long as I keep my E and my Cholesterol in check and don't get lazy with what I need to do, my PSA stays on the decimals. It has never been over 1. If I let the E elevate, it elevates with E. As per most studies I have seen of late, BPH has little to do with DHT levels but ratio to Estrogen. If I had BPH I would treat it with increased DHT and antiaromitazes. |
| |||
|
I find this subject to be very interesting, especially with regard to the possibility that transdermal DHEA does not convert to Estrogen. What about sublingual DHEA? I would imagine that it also does not convert to Estrogen. |
| |||
|
One of the interesting reported DHEA effects is increase in HGH. I notice the mention of IGF-1 in the study as well. I see reported that oral DHEA, while poorly bio available as DHEA, is an inducer of IGF-1 by its metabloites. Now, is the same IGF-1 effect present in transdermal and if so, is it greater or less than oral doses. I do some oral at bedtime with melatonin, 2 grams of glutamine, 2 grams of argenine and 50 DHEA... strictly for HGH -> IGF-1. I do transdermals of T, Andro, and DHEA for optimal TT and free T, but not for growth factor. If transdermal gives the proper metabolites to induce IGF-1, can I drop the oral? Just thinking.
|
| |||
|
So I had 15mg/ml compounded into my T Cream and was using .8ml/day. After about a week I broke out(acne) REALLY BAD! I'm talking on my chest, stomach, shoulders, and back. I've been on T since June with hardly a zit. Wonder what could have caused this? Another interesting thing I've noticed is that when I started the transdermal DHEA, I also added synthroid to my armour. Went Hyper real quick. Thing is, I dropped the synthroid and went back to my original armour dosage and I keep going hyper. I'm thinking the increased DHEA had an effect on my thyroid.
Last edited by SPE; 11-07-2005 at 06:40 PM. |
| |||
| Quote:
|
| |||
|
I posted the following on the Yahoo! Hypogonadism2 forum and thought I'd post it here as well: The 3% oral bioavailability figure for DHEA that is touted about on different websites is apparently taken from a 1996 rat study (I've copied the abstract below). There are at least a half-dozen other actual human studies that show that a 25-50mg oral dose of DHEA gives a very significant increase in DHEA and (more importantly) DHEA-S levels, increasing levels from low normal (and even from well below normal in Addison's patients) to at least mid-range. So obviously, oral bioavailability is reasonable. In humans, oral bioavailability is probably more on the order of 10 times 3%, or 30%. Transdermal is apparently more efficient in elevating serum levels of DHEA, but it also bypasses first-pass liver sulfation, which means you get less formation of the storage form, i.e., DHEA-S. My thinking is that it's nice to have good DHEA numbers, but what you probably really want is good DHEA-S numbers for the "long haul." Frank J Endocrinol. 1996 Sep;150 Suppl:S107-18. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. Labrie C, Flamand M, Belanger A, Labrie F. Laboratory of Molecular Endocrinology CHUL Research Center, Quebec, Canada. Dehydroepiandrosterone (DHEA) administered percutaneously by twice daily application for 7 days to the dorsal skin of the rat stimulates an increase in ventral prostate weight with approximately one third the potency of the compound given by subcutaneous injection. The doses required to achieve a 50% reversal of the inhibitory effect of orchiectomy are approximately 3 and 1 mg respectively. By the oral route, on the other hand. DHEA has only 10-15% of the activity of the compound given percutaneously. Taking the bioavailability obtained by the subcutaneous route as 100%, it is estimated that the potencies of DHEA by the percutaneous and oral routes are approximately 33 and 3% respectively. Similar ratios of activity were obtained when dorsal prostate and seminal vesicle weight were used as parameters of androgenic activity. When examined on an estrogen-sensitive parameter, namely uterine weight in ovariectomized rats, the stimulatory effect of DHEA was much less potent than its androgenic activity measured in the male animal, a 50% reversal of the inhibitory effect of ovariectomy on uterine weight being observed at the 3 and 30 mg doses of DHEA administered by the subcutaneous and percutaneous routes respectively. When measured on uterine weight, percutaneous DHEA thus shows a 10% potency compared with the subcutaneous route. The sulfate of DHEA (DHEA-S), on the other hand, was approximately 50% as potent as DHEA at increasing ventral prostate weight after subcutaneous or percutaneous administration. When the effect was measured on dorsal prostate and seminal vesicle weight, percutaneous DHEA-S had 10-25% of the activity of DHEA. DHEA decreased serum LH levels in ovariectomized animals, an effect which was completely reversed by treatment with the antiandrogen flutamide. On the other hand, flutamide had no significant effect on the increase in uterine weight caused by DHEA, thus suggesting a predominant estrogenic effect of DHEA at the level of the uterus and an estrogenic effect on the feedback control of LH secretion. The present data show a relatively high bioavailability of percutaneous DHEA as measured by its androgenic and/or estrogenic biological activity in well-characterized peripheral target intracrime tissues in the rat. PMID: 8943794 [PubMed - indexed for MEDLINE] |
| |||
|
Good stuff Frank, I had read that study before. I don't have one on human oral DHEA that shows the 30%, just ones that show lower bioavailability. I will take your word for it. Any oral steroid has to get hit with first pass anyway as I understand the physiology, I do believe DHEA may fare better than T or andro. The one study I have that again is interesting is using DHEA to induce a post adolsecent puberty response at very high doses. I have no idea of the entry route. This could be a bogus study... it need to be repeated a few times. DHEA is a very interesting steroid with documented antiaging properties. I think DHEA/HGH is as important as TRT in maintaining virility in middle aged men. I think this is the future personally, just elevating T is not enough. IGF-1 and Dopamine have to come up as well. |
| |||
| Quote:
Elevated DHT to supraphysiologic levels? |
| |||
| Quote:
Last edited by smitty4; 11-11-2005 at 12:16 PM. |
![]() |
| Thread Tools | |
| Display Modes | |
| |
Similar Threads | ||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Injecting testosterone subcutaneously | frankwhardy | Men's Health Forum | 110 | 02-04-2007 12:56 PM |
| DHEA As TRT Protocol | stat1951 | |||